Goal guide
Peptides for Sleep and Recovery: What the Evidence Shows
The peptide with a large randomized sleep trial behind it is tirzepatide, and it was tested for obstructive sleep apnea rather than for sleep quality. The compounds actually sold for sleep — delta sleep-inducing peptide, epithalon, pinealon — have a different profile: a 2006 review called DSIP's link to sleep extremely poorly documented, and as of August 2026 a ClinicalTrials.gov intervention search for either name returns zero studies.
5
1
1
3
Ranked by evidence
What actually has evidence behind it
Ordered by how far the published human evidence goes — strongest first. Availability is a separate question from evidence, so it is labeled separately.
Tirzepatide (Zepbound, Mounjaro)
FDA-approvedRandomized trialsEvidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
What it is
A weekly GIP and GLP-1 receptor agonist. It is on this page because of one large trial programme in obstructive sleep apnea, not because it is a sleep drug.
What the evidence shows
SURMOUNT-OSA ran two 52-week randomized trials in adults with moderate-to-severe obstructive sleep apnea and obesity, with a mean baseline apnea-hypopnea index of 51.5 and 49.5 events per hour. In trial 1, AHI fell 25.3 events per hour on tirzepatide against 5.3 on placebo, a treatment difference of 20.0. In trial 2, AHI fell 29.3 against 5.5, a difference of 23.8. Hypoxic burden, hsCRP, systolic blood pressure and sleep-related patient-reported outcomes all improved against placebo. The most frequent adverse events were gastrointestinal.1
The catch
This treats sleep apnea, and it treats it largely by treating obesity — participants had a mean BMI near 39. If your sleep is poor for a reason other than an obstructed airway, nothing in this trial applies to you. The gastrointestinal side effects that come with this drug class came with it here too — they were the most frequently reported adverse events in both trials.
Approved for this use and available by prescription.
GHRH peptides (tesamorelin, sermorelin)
Compounding restrictedEarly humanEvidence strength: Early human. Small, open-label, or phase 1/2 trials. Promising, unproven.
What it is
Growth-hormone-releasing hormone analogs. Sleep is the one place where the growth-hormone axis has a genuine, long-documented electrophysiological effect.
What the evidence shows
A 1997 review of neuropeptides and human sleep reports that in young normal subjects, GHRH stimulates slow-wave sleep and growth hormone secretion while inhibiting cortisol release, and that the balance between GHRH and corticotropin-releasing hormone shifts toward CRH during normal ageing and acute depression, disturbing sleep-endocrine activity. Galanin, growth-hormone-releasing peptide and neuropeptide Y are reported as sleep-promoting in the same review, while it describes the impact of delta sleep-inducing peptide on human sleep regulation as not yet clear.2
The catch
A shift in the sleep EEG in a laboratory is not a treatment for a sleep complaint, and the registry record here is unusually stark. As of August 2026, a ClinicalTrials.gov intervention search for tesamorelin returns 24 studies; the two concerning sleep — a phase 2 in service members with traumatic brain injury and insomnia, and a study of sleep-disordered breathing in lipodystrophy — were both withdrawn with zero participants enrolled. A separate search for sermorelin returns 27 studies, including one completed study of GHRH for age-related sleep disturbance that ran from June 1996 to July 2007 and has posted no results.
Under active FDA restriction — compliant pharmacies decline to sell it.
Delta sleep-inducing peptide (DSIP)
Research use onlyAnimal onlyEvidence strength: Animal only. Rodent or cell studies. Nothing published in humans.
What it is
A nine-amino-acid peptide isolated from rabbit cerebral venous blood in 1977 and named for the effect its discoverers hoped it produced.
What the evidence shows
A 2006 review in the Journal of Neurochemistry states that the link between DSIP and sleep has never been further characterised, in part because the DSIP gene, protein and possible receptor have not been isolated, and describes the hypothesis of DSIP as a sleep factor as extremely poorly documented and still weak. The same review reports that certain artificial DSIP structural analogues — but not DSIP itself — promoted slow-wave sleep in rabbits and rats. A 2026 orthopaedic review lists DSIP among recovery-enhancing peptides targeting circadian and mitochondrial regulators, alongside a stated current lack of clinical trials.2,3,4
The catch
Its own literature says the analogues worked and the peptide did not. Nearly fifty years after isolation, the receptor has not been identified, and as of August 2026 a ClinicalTrials.gov intervention search for either 'delta sleep-inducing peptide' or 'DSIP' returns zero studies. The name is a hypothesis from 1977, not a finding.
Sold for laboratory use. Not a legal medicine for people.
Epithalon and pinealon
Research use onlyAnimal onlyEvidence strength: Animal only. Rodent or cell studies. Nothing published in humans.
What it is
Short synthetic peptides sold as circadian and 'recovery' agents, usually alongside longevity claims.
What the evidence shows
A 2026 orthopaedic review groups epithalon, pinealon and DSIP as recovery-enhancing agents targeting circadian and mitochondrial regulators, and states that although preclinical studies are promising, there is a current lack of clinical trials across the peptides it covers.4
The catch
As of August 2026, a ClinicalTrials.gov intervention search returns zero studies for epithalon and zero for the alternate spelling epitalon. A compound sold to regulate your circadian rhythm, with no registered trial measuring anyone's sleep.
Sold for laboratory use. Not a legal medicine for people.
BPC-157 and TB-500
Research use onlyAnimal onlyEvidence strength: Animal only. Rodent or cell studies. Nothing published in humans.
What it is
Tissue-repair peptides, frequently sold as part of a 'recovery' stack in which better sleep is an implied benefit.
What the evidence shows
A 2026 sports medicine review of approved and unapproved peptide therapies places both among compounds with favourable animal tissue-repair results and scarce rigorous human safety data. A 2026 orthopaedic review classifies them as wound-healing peptides acting on angiogenesis and matrix remodelling — a mechanism about tissue, not about sleep.4,5
The catch
The sleep claim for these is inference, not evidence: recover better, sleep better. No trial in either compound measured a sleep endpoint. What they were actually tested for is covered on our injury page, and the answer there is thin too.
Sold for laboratory use. Not a legal medicine for people.
The trial that exists
SURMOUNT-OSA is the largest randomized sleep-outcome result for any peptide: two 52-week trials in adults with moderate-to-severe obstructive sleep apnea and obesity, with the apnea-hypopnea index falling 25.3 and 29.3 events per hour against 5.3 and 5.5 on placebo 1.
That is a real, large effect on a hard endpoint. It is also specifically about an obstructed airway in people with a mean BMI near 39, and tirzepatide is a weight drug that happens to relieve it. If your problem is falling asleep, staying asleep, or waking unrefreshed without apnea, this trial is not about you.
The one mechanism that is genuinely about sleep
The growth-hormone axis and sleep are linked, and this is old, careful work rather than marketing. A 1997 review reports GHRH stimulating slow-wave sleep and growth hormone secretion in young normal subjects while suppressing cortisol, and describes the GHRH-to-CRH balance shifting with ageing and depression in a way that disturbs sleep 2.
What did not follow is a treatment. As of August 2026, the two sleep studies in the tesamorelin registry set were both withdrawn with zero participants enrolled, and the one completed GHRH study in age-related sleep disturbance — begun in June 1996, completed in July 2007 — has posted no results. A mechanism can be well described for thirty years and still produce no usable trial.
What DSIP's own literature says
The compound sold hardest for sleep is delta sleep-inducing peptide, and the most informative thing about it is what its own review literature concluded. In 2006 the *Journal of Neurochemistry* published a review titled "a still unresolved riddle," which states the DSIP-sleep link has never been further characterised, calls the sleep-factor hypothesis extremely poorly documented and still weak, and notes that artificial DSIP analogues promoted slow-wave sleep in rabbits and rats while DSIP itself did not 3.
That was twenty years ago. As of August 2026, a ClinicalTrials.gov intervention search for the compound returns zero studies.
What would change this page
A registered randomized trial with a sleep endpoint — polysomnography, sleep latency, or a validated questionnaire — in any of the compounds sold for this. A 2026 orthopaedic review that covers DSIP, epithalon and pinealon alongside BPC-157 and TB-500 states the position plainly: preclinical studies are promising, and clinical trials are currently lacking 4. Our injury-recovery page covers the same compounds against the outcome they are more often sold for.
Questions
Frequently asked questions
Is there a peptide that improves sleep?
None with a randomized sleep-endpoint trial. The peptides marketed for sleep — delta sleep-inducing peptide, epithalon, pinealon — return zero studies each in a ClinicalTrials.gov intervention search as of August 2026. The peptide with a large randomized sleep result is tirzepatide, and it was tested for obstructive sleep apnea in people with obesity.
Does DSIP actually induce sleep?
Its own review literature is unusually blunt. A 2006 Journal of Neurochemistry review states the DSIP-sleep link has never been further characterised, calls the sleep-factor hypothesis extremely poorly documented and still weak, and reports that artificial structural analogues promoted slow-wave sleep in rabbits and rats while DSIP itself did not. The receptor has not been isolated.
What did the tirzepatide sleep apnea trial find?
SURMOUNT-OSA ran two 52-week randomized trials in adults with moderate-to-severe obstructive sleep apnea and obesity. The apnea-hypopnea index fell 25.3 events per hour against 5.3 on placebo in trial 1, and 29.3 against 5.5 in trial 2. Hypoxic burden, hsCRP, systolic blood pressure and sleep-related patient-reported outcomes also improved. Baseline BMI averaged around 39.
Do growth hormone peptides help you sleep deeper?
GHRH does change the sleep EEG — a 1997 review reports it stimulating slow-wave sleep in young normal subjects while suppressing cortisol. That is a laboratory finding, not a treatment. As of August 2026 the two sleep studies in the tesamorelin registry set were both withdrawn with zero participants enrolled, and the one completed GHRH study in age-related sleep disturbance, run from 1996 to 2007, has posted no results.
Keep reading
Go deeper on one compound
Sources
References
- Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/38912654/
- Steiger A, Holsboer F (1997). Neuropeptides and human sleep. Sleep. https://pubmed.ncbi.nlm.nih.gov/9456470/
- Kovalzon VM, Strekalova TV (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/16539679/
- Rahman OF, Lee SJ, Seeds WA (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Global Research & Reviews. https://pubmed.ncbi.nlm.nih.gov/41490200/
- Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.